History

2003-2005: Organisation and structuring

2003 Creation of the Novacap group, Bain Capital is the group’s majority shareholder

2004 Launch of a new sodium bicarbonate unit

2006-2011: Organic development improvement

2006 Launch of the calcium chloride unit in Pont-de-Claix

2008 Launch of the second sodium bicarbonate unit

2010 Launch of the Isopropanol unit in Roussillon

2011 Ardian acquires 96% of Novacap

 

 

 

2011-2016: Growth acceleration and internationalisation

2011 Start-up of the third sodium bicarbonate unit

2011 Acquisition of Novacyl, worldwilde leader in  Aspirin, salicylic acid and its derivated

2011 Launch of a new ferric chloride production unit in Pont-de-Claix (France)

2012 Capacity increase on alpha methyl styrene

2013 Acquisition of a majority stake (51%)  in Yangzi Pharmaceutical Chemical in China

2014 Launch of homosalate and sodium silicates.

2014 Acquisition of a 51% majority stake in Puyuan .

2015 Acquisition of Uetikon a German-based APIs and fine chemicals manufacturer.

2015 Novacap enters into a partnership with the innovative biotechnology startup Alganelle, specialised in the development and production of high added-value molecules, derived from microalgae.

2016 EURAZEO becomes the majority shareholder of the group alongside MERIEUX development, ARDIAN and the management team.

 

 

Since 2016 : Strengthening the technological and products offering for the pharmaceutical, cosmetics and fine chemistry markets.

 

2017 Novacap acquires 96.5% of Puyuan

2017 Novacap acquires 77.57% of Yangzi Pharmaceutical Chemical

April 2017 Novacap announced a project of strategic combination with PCAS, specialising in the development and production of complex molecules for life sciences and innovative technologies, through a sale of blocks of shares followed by a tender offer.

April 2017 Launch of a new production unit for manufacturing DIPE (Diisopropyl Ether) on the Roussillon chemical platform.

May 2017 Novacap acquires ID bio, a manufacturer of botanical ingredients and H2B, a manufacturer of ingredients for in-vitro diagnosis.

May 2017 Novacap acquires PCAS aCDMO (Contract Development and Manufacturing Organization)specializes in the development and production of complex molecules for life sciences and innovative technologies.

July 2017 Acquisition of a majority stake in Chemoxy International Ltd, a leading contract manufacturer for specialty chemicals and environmentally-friendly solvents.

December 2017 Novacap supports Harmonic Pharma, an innovative company specialized in Polypharmacology through a capital increase.

June 2018: Novacap acquires PCI Synthesis, a Pharmaceutical Development CDMO based in Newburyport, MA